Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Ryan Stadel, Ruifu Liu, Yosef Landesman, David Wald, Smitha Hosahalli Vasanna, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7413–7414.

https://doi.org/10.1182/blood-2022-164443

Published: 2022

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Blood (2022) 140 (Supplement 1): 1885–1886.

https://doi.org/10.1182/blood-2022-169336

Published: 2022

Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 7457–7459.

https://doi.org/10.1182/blood-2022-170629

Published: 2022

Journal Articles

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Sumithira Vasu, Lapo Alinari, Nicole Szuminski, Dina Schneider, Nathan Denlinger, Wing Keung Chan, Khalid Parris, Nidhi Sharma, Hillary Bradbury, Beth Daneault, Lynn O'Donnell, Boro Dropulic, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7474–7475.

https://doi.org/10.1182/blood-2022-167340

Published: 2022

Journal Articles

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Marcos J.G. de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Michael T Hemmer, Mei-Jie Zhang, Fan Zhang, Richa Shah, Verna Welch, Saara Tikka, Erik Vandendries, Matthias Stelljes, David I. Marks, Wael Saber

Blood (2022) 140 (Supplement 1): 6023–6025.

https://doi.org/10.1182/blood-2022-160315

Published: 2022

Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 1887–1889.

https://doi.org/10.1182/blood-2022-169935

Published: 2022

Journal Articles

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

Zachary Jackson, Changjin Hong, Robert Schauner, Boro Dropulic, Paolo F. Caimi, Marcos J.G. de Lima, Kalpana Gupta, Jane Reese, Tae Hyun Hwang, David Wald

Blood (2021) 138 (Supplement 1): 164.

https://doi.org/10.1182/blood-2021-152813

Published: 2021

Journal Articles

Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study

Omar H Butt, Alice Y. Zhou, Paolo F. Caimi, Paul-Robert Derenoncour, Kenneth Lee, Gregory F Wu, Marcos J.G. de Lima, John F. DiPersio, Jian L. Campian, Armin Ghobadi, Beau M Ances

Blood (2021) 138 (Supplement 1): 2841.

https://doi.org/10.1182/blood-2021-149674

Published: 2021

Journal Articles

Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study

Sumithira Vasu, Meghan Kromer, Qiuhong Zhao, Hannah Choe, Karilyn Larkin, Sarah A Wall, Samantha Jaglowski, Sam Penza, Jonathan E Brammer, Nidhi Sharma, Naduparambil Jacob, Marcos J.G. de Lima, Meng Welliver

Blood (2021) 138 (Supplement 1): 2856.

https://doi.org/10.1182/blood-2021-150948

Published: 2021

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, Nidhi Sharma, Alison R. Walker, Sarah A Wall, James S. Blachly, Greg K. Behbehani, Hannah Choe, Aarohi Thakkar, Robin Nakkula, Ella Troy, Nicole Szuminski, Marcos J.G. de Lima, Lynn O'Donnell, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2021-150750

Published: 2021

Journal Articles

Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution

Audrey M. Sigmund, Nathan Denlinger, Amneet Bajwa, Patrick Elder, David A. Bond, Jonathan E Brammer, Ayman Saad, Sam Penza, Marcos J.G. de Lima, Samantha Jaglowski, Adam S Kittai

Blood (2021) 138 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2021-148751

Published: 2021

Journal Articles

Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma

Ehsan Malek, Mary Hislop, Leland Metheny, III, Molly Gallogly, Marcos J.G. de Lima, Farhad Sanati, Hannah Elizabeth Schmikla, Brett Glotzbecker, James Driscoll

Blood (2021) 138 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2021-148220

Published: 2021

Journal Articles

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2021) 138 (Supplement 1): 3933.

https://doi.org/10.1182/blood-2021-146334

Published: 2021

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Blood (2021) 138 (Supplement 1): 553.

https://doi.org/10.1182/blood-2021-152833

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Cardiac Arrhythmias and Mortality after Hematopoietic Stem Cell Transplant (HSCT): A Systematic Review and Meta-Analysis

Saad Ullah Malik, Zachary Braunstein, Sumithira Vasu, Sam Penza, Ayman Saad, Nathan Denlinger, Marcos J.G. de Lima, Ajay Vallakati, Ragavendra Baliga, Samantha Jaglowski, Jonathan E. Brammer, Daniel Addison

Blood (2021) 138 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2021-152223

Published: 2021

Journal Articles

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Basem M. William, John C. Reneau, Amanda Campbell, Anna Vilgelm, Michelle Watts, Lynn O'Donnell, Ying Huang, Catherine Chung, Marcos J.G. de Lima, Steven Devine, Sumithira Vasu, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2021-150543

Published: 2021

Journal Articles

Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis

Michael M. Boyiadzis, Marcos J.G. de Lima, Mei-Jie Zhang, Karen Chen, Christopher S. Hourigan, Partow Kebriaei, Mark R. Litzow, Kristin M. Page, Wael Saber, Daniel J. Weisdorf

Blood (2021) 138 (Supplement 1): 414.

https://doi.org/10.1182/blood-2021-149962

Published: 2021

NARROW

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study

Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution

Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Cardiac Arrhythmias and Mortality after Hematopoietic Stem Cell Transplant (HSCT): A Systematic Review and Meta-Analysis

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only